Physician profile
Mohammad E Taher
NPI 1992762918
$44,708.01
in general payments reported to CMS, 2019-2025
56 companies · $2,103 in 2025
The $2,103 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,952 · 2020: $3,528 · 2021: $15K · 2022: $2,589 · 2023: $9,955 · 2024: $8,810 · 2025: $2,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $7,873 · Travel and Lodging: $169 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,675.00 |
| Food and Beverage | $7,872.87 |
| Travel and Lodging | $168.92 |
| Education | $151.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,422.32 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $10,950.26 | 2021 | |
| Allergan, INC. | $3,375.24 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,075.99 | 2019-2024 | |
| Biogen, INC. | $1,004.75 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Neurocrine Biosciences, INC. | $871.33 | 2019-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $849.10 | 2019-2023 | |
| Ucb, INC. | $702.74 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Amneal Pharmaceuticals LLC | $663.33 | 2019-2025 | Rytary, Ongentys, Crexont |
| Emd Serono, INC. | $642.91 | 2019-2025 | Mavenclad |
| Mdd US Operations, LLC | $593.14 | 2019-2024 | Gocovri |
| Argenx US, INC. | $562.57 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Livanova USA, INC. | $561.65 | 2019-2024 | Vns Therapy |
| Sk Life Science, INC. | $556.57 | 2020-2024 | Xcopri |
| Lilly USA, LLC | $550.18 | 2019-2025 | Amyvid, Emgality, Reyvow |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Taher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.